Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deprilium is a multi-ingredient nutraceutical developed by NutriMed Group, formulated to support mental health and emotional stability. Its primary active components include S-adenosyl-L-methionine (SAMe), levomefolic acid (L-methylfolate), and mecobalamin (Vitamin B12). SAMe serves as a critical methyl donor in the central nervous system, participating in the synthesis of key neurotransmitters such as serotonin, dopamine, and norepinephrine, which regulate mood and cognitive function. Levomefolic acid and mecobalamin act as essential cofactors in the one-carbon metabolism cycle, facilitating the remethylation of homocysteine to methionine and ensuring the continuous availability of SAMe. This combination is intended to address nutritional deficiencies that may contribute to depressive symptoms, anxiety, and emotional instability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Deprilium.